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Cyclosporin A prevents the anti-murine antibody response to a
monoclonal anti-tumour antibody in rabbits
J.A. Ledermann, R.H.J. Begent & K.D. Bagshawe
Cancer Research Campaign Laboratories, Department of Medical Oncology, Charing Cross Hospital, London W6 8RF, UK.
Summary Repeated therapy of cancer with mouse monoclonal antibodies frequently produces antibodies
directed against the administered antibody. We have investigated the ability of cyclosporin A (CsA) and the
use of ultracentrifuged antibody to prevent the formation of anti-antibodies in rabbits. Courses of CsA,
20mgkg-1day-1, were given intramuscularly for 6 days to rabbits and a mouse monoclonal anti-human
chorionic gonadotrophin antibody was given intravenously on day 2 with or without ultracentrifugation to
remove microaggregates. The whole course was repeated after an interval of two weeks. Rabbit anti-mouse
antibody production was prevented in all 8 animals that were given CsA and ultracentrifuged antibody (UC-
W14). Anti-mouse antibody was detected in 2/8 rabbits given CsA and a non ultracentrifuged preparation
(non UC-W14). Anti-mouse antibody was produced by all the animals that were not given CsA. A further
dose of mouse antibody eight weeks after CsA demonstrated that immunological recovery had occurred in all
four animals re-challenged with non UC-W14 but only 3/7 animals given an UC-W14 preparation. This
suggests that CsA and ultracentrifugation facilitate the induction of immunological tolerance. The complete
suppression of antibody production which could be achieved justifies a clinical trial of CsA and ultra-
centrifugation of antibody.
Most patients who are given monoclonal antibodies for the
therapy of cancer produce a human anti-antibody response.
This may lead to accelerated clearance of subsequent doses
of the monoclonal antibody from the circulation, reduced
binding to the target tissue and hypersensitivity reactions
(Sears et al., 1982; Miller et al., 1983, Carrasquillo et al.,
1984; Meeker et al., 1985). For effective therapy it is likely
that antibody conjugates will need to be given on several
occasions so it is important to develop a reliable method of
preventing the immune response to xenogeneic antibodies.
Several approaches to the prevention of anti-antibody
production in man have been investigated and these include
the use of immunoglobin fragments (Carrasquillo et al.,
1984), immunosuppressive drugs (Miller et al., 1983;
Thistlethwaite et al., 1984), and induction of immunological
tolerance (Taub et al., 1969, Sears et al., 1984). These
methods have had limited success but it has been possible to
induce tolerance to equine anti-lymphocyte globulin in some
patients pre-treated with cytotoxic immunosuppressive drugs
and equine immunoglobulin G that had been 'deaggregated'
by ultracentrifugation (Rossen et al., 1971). Ultra-
centrifugation of antibody removes microaggregates and has
been used to induce immunological tolerance in animals
(Dresser, 1962).
Cyclosporin A (CsA) is a non-cytotoxic immunosuppressive
agent. It is a powerful inhibitor of the humoral immune
response (Borel et al., 1976) but this action has received less
attention than its effect on cell-mediated immunity. It
prevents the primary but not secondary immune response in
vivo (Lindsey et al., 1982) but it is not known whether
antibody production in response to repeated doses of an
immunogen can be prevented by giving CsA with each
course. We have given CsA and a mouse monoclonal anti-
tumour antibody to rabbits to test whether CsA and ultra-




Thirty-two New Zealand white rabbits weighing from 1.5 to
3.3 kg (mean 2.3 kg) were used; they were immature and
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male and female animals were distributed evenly between the
different groups.
Monoclonal antibody
The mouse monoclonal antibody (W14), an IgG1 anti-
human chorionic gonadotrophin (hCG), was produced either
in mouse ascites or cell free supernatant and immunopurified
on an hCG-sepharose column as previously described (Searle
et al., 1984). Ultracentrifugation was performed after the
method of Rossen et al. (1971). Briefly, samples in 0.2M
phosphate buffer were centrifuged in two stages, each at
48,000g at 4°C for 1 h. After the first stage the top two-
thirds of the original sample were re-centrifuged and the top
third of this was used for injection. The protein content was
measured by absorbance at 280nm.
Immunosuppression
Cyclosporin A was dissolved in Miglyol 812 (Dynamit
Nobel, UK) and ethanol to 100mgml-1 and given
intramuscularly into the hind quarter. Miglyol has been
shown not to affect the immune response (Smith, 1982).
Immunization protocol
The schedule and details of antibody are given in Figure 1.
Antibody (W14) was given in 2 doses 14 days apart to all
groups. In group I W14 was ultracentrifuged (UC-W14) and
CsA was given daily for 6 days starting 2 days before each
dose of antibody. In group 2 CsA was given but antibody
was not ultracentrifuged (non UC-W14). In group 3 CsA
was not given and antibody was UC-W14. In group 4 CsA
was not given and antibody was non UC-W14. The
experiments were conducted with 4 rabbits in each group
and then repeated. The combined results for 8 animals in
each group are shown. Groups 1, 2, and 3 of this second
batch of rabbits received W14 produced in supernatant
culture as ascites-derived antibody was not available.
Animals were bled from the lateral ear vein, before, 30min
after injection and then at regular intervals during the next
28 days. Samples for 125-iodine (125I) activity were counted
on a gamma counter and assayed for rabbit anti-mouse
antibody.
Rabbit anti-mouse assay
The monoclonal antibody W14, 200ng per well, in 0.05M
phosphate buffer was dried onto polyvinyl microtitre plates
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and then fixed with methanol. All samples were diluted in
0.03 M PBS with 0.05% Tween and 0.1% bovine serum
albumin and were incubated at room temperature. Dilutions
(100 Mlu) of serum were incubated for 3h and then for 2h
with goat anti-rabbit IgG labelled with alkaline phosphatase
(Sigma). The wells were washed with PBS-Tween between
each stage and the reaction was developed by adding p-
nitrophenyl phosphate (Sigma) in 10% diethanolamine-HCL
pH9.8 with 2mm MgCl2 for 15min. The absorbance was
read at 405nm on a Titertek Multiskan. The assay was
standardized with rabbit anti-mouse serum, raised against
W14 and immunopurified on a mouse IgG-sepharose
column and the protein content calculated from the
absorbance at 280nm. The purity of the standard was
checked on sodium dodecyl sulphate polyacrylamide gel
electrophoresis.
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Figure 1 Immunization protocol. Four rabbits per group. CsA,
20mgkg-I given intramuscularly. Either UC-W14 or non UC-
W14 (200 ig), containing an additional 8 g UC-W14 labelled
with 80MCi 12 I by the lodogen method was given to each animal.
This injection was repeated on day 16.
Results
Clearance of 125I monoclonal antibody from blood
The clearance of 1251 W14 measured in whole blood
accelerated after the 6th day in the rabbits that had not
received CsA (groups 3 and 4) (Figure 2a). This acceleration
coincided with the first detectable rabbit anti-mouse
antibody. In contrast, the rate of elimination of 1251 W14
was constant in the animals that received CsA (groups 1 and
2). The mean antibody half-life was 1.9 days (s.d.=0.41).
Fourteen days after the first injection group 1 (UG-W14 and
CsA) had significantly more labelled antibody in the
circulation than group 3 (UG-W14) (P<0.01) (Figure 2a).
On day 16 a second injection of W14 was given (Figure
2b). The elimination half-life of antibody in animals given
CsA (groups 1 and 2) did not differ significantly from the
first injection. A rapid clearance of label was seen within
thirty minutes of injection of W14 in the animals that had
developed antibodies after the first injection and again at the
end of the second fourteen day period significantly more
antibody remained in group 1 (UC-W14 and CsA) compared
with group 3 (UC-W14) (P<0.01). The clearance of 125I
W14 in group 3 did not differ from the pattern of
elimination seen in group 4 (non UG-W14). A similar
pattern of elimination of 1251 W14 was seen when the
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Figure 2 The clearance of 1251 mouse anti-hCG (W14) in four
groups of 4 rabbits: * Group 1 (UC-W14 and CsA); 0 Group 2
(non UC-W14 and CsA); * Group 3 (UC-W14); [l Group 4
(non UC-W14). In (a), the first sample was taken 30min after
injection on day 2. In (b), it was 30min after the injection on day
16. Group I received 1.4 times the amount of 125I given to the
other groups.
Rabbit anti-mouse antibody response
The amount of rabbit anti-mouse antibody in rabbit sera
was quantified by an enzyme assay and values were derived
from a series of dilution curves which were shown to be
parallel to an immunopurified standard. Anti-mouse
antibody was not detected before immunization. The assay
was able to detect 0.1 gml-1, or more, of anti-mouse
antibody. The results in both sets of experiments have been
combined. None of the 8 animals that were given CsA in
combination with ultracentrifuged W14 (UC-W14) made
rabbit anti-mouse antibody (Figure 3a). However, anti-
mouse antibody was present in 2/8 animals given CsA and
non UC-W14 (Figure 3b) following the first injection but no
further elevation in the anti-mouse level was seen after the
second injection. All 16 animals that were not given CsA
made anti-mouse antibody after four weeks.
The immune pattern of clearance and the presence of anti-
mouse antibody in the eight animals given UC-W14 without
CsA indicated that immunological tolerance to ultra-
centrifuged W14 had not occurred (Figure 3c). However, the
quantity of antibody secreted varied greatly. Less antibody
was produced by the 4 animals given antibody prepared
from supernatant culture (P<0.02). All the control animals
received antibody prepared from ascites and they made a
good immune response after the first and second injections
(Figure 3d).
Recovery of immune response after cyclosporin A
Eleven rabbits that failed to make anti-mouse antibody while
on CsA were challenged with a third intravenous dose of
200 g W14 without CsA 8 weeks after the completion of
CsA therapy to determine whether they had recovered the
ability to respond to mouse antibody. All 4 animals that
were given non UC-W14 developed anti-mouse antibody
(Figure 4). However, 3/7 rabbits given UC-W14 still failed to
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Figure 3 Rabbit IgG anti-mouse antibody response. (a) Group 1 (CsA and UC-W14); (b) Group 2 (CsA and non UC-W14); (c)
Group 3 (UC-W14); (d) Group 4 (non UC-W14). RAMA=rabbit anti-mouse antibody. Results <0.1 pgml- are shown below
the dotted line. In (c) s=W14 produced in supernatant cell culture.
make anti-mouse antibody. Two of the non-responders were
then given 400 ug of non UC-W14 intravenously 2 weeks
later and both animals remained unresponsive to mouse






Figure 4 Rabbit IgG anti-mouse antibody (RAMA) response 8
weeks after CsA therapy.
two animals were from group 2. The quantity of anti-mouse
antibody produced by the 8 rabbits was similar to the
amount detected in the animals after primary challenge with
the monoclonal antibody (Figure 3d).
The animals that responded poorly to W14 produced in
supernatant cell culture (Figure 3c) were given 200Mg ascites-
derived W14 intravenously 8 weeks after the completion of
CsA. It was possible to boost the antibody response in 3/4 of
these animals. The one poor responder also produced only a
low titre of antibody (by a double antibody filtration
radioimmunoassay) to 200,pg bovine albumin that had been
injected into all 4 rabbits at the same time to test their
immunocompetence. The remaining 3 animals produced high
levels of antibody to bovine albumin.
The elimination of 1251 W14 in the animals re-challenged
with UC-W14 demonstrated a pattern of immune clearance
seen in a primary-type immune response (Figure 5). There
was a lag period before immune clearance and anti-mouse
antibody first appeared. The antibody half-life in the tolerant
animals remained prolonged and was not significantly
different from the non-responders in Figure 2.
Discussion































Figure 5 Clearance of 1251 anti-hCG (W14) in animals re-
challenged with UC-W14 8 weeks after CsA therapy.
suppression produced by CsA prevented anti-antibody
formation to repeated administration of an anti-tumour
monoclonal antibody. The purpose of the investigations was
to find an effective method of abrogating the humoral
immune response in animals that could be applied to
patients who receive monoclonal antibody therapy. Various
approaches to inducing immunological tolerance to
monoclonal antibodies were considered. Anti-mouse
antibodies are found less frequently in patients given an
*injection of a large dose of mouse anti-tumour antibody
(Sears et al., 1984b). However, given weekly, this dose did
not lead to tolerance (Saleh et al., 1986). The elimination of
antigen-specific antibody forming cells by exposure to radio-
labelled antigen has been achieved in mice (Ada & Byrt,
1969) but not in patients, as treatment with large doses of
radioiodinated anti-tumour antibodies does not abolish the
anti-antibody response (Carrasquillo et al., 1984).
Alternatively, antibodies with low immunogenicity such as
human-mouse hybrid antibodies or fragments with a mouse
variable region and human constant region could be used
(Riechmann et al., 1988). It is unclear whether these
antibodies would lead to the generation of an anti-idiotypic
response which can also be detected in up to 60% of patients
treated with the mouse anti-T cell antibody OKT3 (Jaffers et
al., 1986).
As anti-antibodies are not usually found in patients who
have tumours associated with marked immunosuppression of
the host (Schroff et al., 1985; Shawler et al., 1985) it is
rational to use immunosuppressive agents to abrogate the
anti-antibody response. However, previous experience with
immunosuppressive agents has shown that the anti-antibody
response has been suppressed only in a proportion of
patients who received a combination of steroids. aza-
thiopr-ine and cyclophosphamide (Thisllethwaitc et ilt., 1986).
CsA was selected for these experiments as large doses
produce profound suppression of humoral immunity in
animals without the bone marrow suppression seen with
cyclophosphamide and azathioprine (Borel et al., 1976).
The suppression of humoral immunity has been shown to
depend upon the dose of CsA and, in rabbits, the effective
dose of intramuscular CsA lies between 10 and
25mg kg 1 day 1 (Harris et al., 1982). Short courses of CsA
were used to reduce toxicity. This schedule was effective as
maximum immunosuppression occurs when the drug is given
around the time of immunization (Borel et al., 1977). The
animals failed to grow while receiving CsA but with the
exception of one rabbit, grew normally after the completion
of the experiments. The principal action of CsA is an
inhibition of T helper cell function which occurs during the
early phase of immunization (Hess et al., 1986). We have
shown that this inhibitory effect is maintained if the drug is
given both before primary exposure to the immunogen and
again with a repeated challenge of the monoclonal antibody.
These in vivo findings have confirmed the results of
adoptive transfer experiments in mice which showed that
although T helper cell priming occurs normally in the
presence of CsA, T helper effector function remains inhibited
as long as the drug is continued (Kunkl & Klaus, 1983). The
mechanism of this action remains unclear but it appears that
'memory cells' fail to develop as long as CsA therapy is
continued. This is supported by the primary-type biphasic
clearaince of 125I W14 with a lag period before immune
elimination of antibody, seen when the animals were re-
challenged eight weeks after CsA therapy (Figure 5). This lag
phase probably represents the time required for T helper
cells to act on previously naive antibody-forming cells.
Furthermore, the amount of anti-mouse antibody formed on
a re-challenge 8 weeks after the completion of CsA therapy
was of the same order of magnitude found in the primary
antibody response (Figure 4).
UC-W14 alone did not lead to immunological tolerance
probably because the doses of immunoglobulin were smaller
than the amount that has been used to induce tolerance in
rabbits (Dresser & Gowland, 1964; Biro & Garcia, 1965). No
qualitative differences in composition were seen when the
centrifuged and uncentrifuged fractions were examined by
high-pressure liquid chromatography. However, it is possible
that ultracentrifugation facilitated the action of CsA as
rabbit anti-mouse antibody was not detected in any animals
receiving UC-W14, but in 2/8 of those given the non
UC-W14.
A variation in the amount of rabbit anti-mouse antibody
produced was seen in the groups receiving UC-W14 (Figure
3c). This could have been due to variations between litters or
preparative procedures as the animals forming low levels of
anti-mouse antibody had been given a monoclonal antibody
derived from supernatant cell culture. A challenge with
bovine albumin and ascites-derived W14 8 weeks after the
last dose of W14 showed that all but one animal was
immunocompetent. There is no a priori evidence to suggest a
difference in immunogenicity exists between antibodies
produced in ascites and supernatant cell culture but further
investigations are being performed to examine this
possibility.
Immunological tolerance to anti-lymphocyte globulin has
been reported in some patients receiving allografts who were
pretreated with immunosuppressive agents and equine
antibody that had been ultracentrifuged (Rossen et al.,
1971). Immunological tolerance also has occasionally been
reported after CsA therapy (Green & Allison, 1978; Smith,
1982). It has been suggested that this is due to a failure of
CsA to inhibit T suppressor cells (Hess et al., 1986). An
absent response to mouse immunoglobulin, seen in 3/7
rabbits that were re-challenged with UC-W14 8 weeks after
the completion of CsA therapy and a large dose of non UC-
W14 2 weeks later sugests that CsA may have facilitated the
induction of tolerance to W14. However, tolerance did not
occur in the animals re-challenged with non UC-W14. The
induction of immunological tolerance to anti-tumour
antibodies observed in rabbits may be less easily achieved in
man as anti-tumour antibodies often become bound to
circulating or tissue bound antigen and this has been shown
to make the establishment of immunological tolerance more
difficult (Benjamin et al., 1986).566 J.A. LEDERMANN et al.
In conclusion, the use of CsA provides an effective
method of abrogating the anti-antibody response to repeated
doses of a monoclonal anti-tumour antibody in rabbits.
Antibody ultracentrifugation may contribute to the effect of
CsA and in some cases this has led to a state of immuno-
logical tolerance. If these effects can be reproduced in
patients it may become possible to administer repeated doses
of antibody targeted therapy of cancer.
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